AU2018217404B2 - Method for generating T cells progenitors - Google Patents

Method for generating T cells progenitors Download PDF

Info

Publication number
AU2018217404B2
AU2018217404B2 AU2018217404A AU2018217404A AU2018217404B2 AU 2018217404 B2 AU2018217404 B2 AU 2018217404B2 AU 2018217404 A AU2018217404 A AU 2018217404A AU 2018217404 A AU2018217404 A AU 2018217404A AU 2018217404 B2 AU2018217404 B2 AU 2018217404B2
Authority
AU
Australia
Prior art keywords
cells
gly
cys
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018217404A
Other languages
English (en)
Other versions
AU2018217404A1 (en
AU2018217404A2 (en
Inventor
Isabelle Andre
Marina Cavazzana
Ranjita Devi Moirangthem
Kuiying MA
Tayebeh-Shabi Soheili
John TCHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondation Imagine - Institut Des Maladies Genetiques
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Cité
Original Assignee
Fondation Imagine Inst Des Maladies Genetiques
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Cité
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondation Imagine Inst Des Maladies Genetiques, Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Université Paris Cité filed Critical Fondation Imagine Inst Des Maladies Genetiques
Publication of AU2018217404A1 publication Critical patent/AU2018217404A1/en
Publication of AU2018217404A2 publication Critical patent/AU2018217404A2/en
Assigned to ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), FONDATION IMAGINE - INSTITUT DES MALADIES GÉNÉTIQUES, Universite De Paris reassignment ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS Request for Assignment Assignors: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FONDATION IMAGINE - INSTITUT DES MALADIES GÉNÉTIQUES, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITÉ PARIS DESCARTES
Assigned to ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), FONDATION IMAGINE - INSTITUT DES MALADIES GÉNÉTIQUES, UNIVERSITÉ PARIS CITÉ reassignment ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS Amend patent request/document other than specification (104) Assignors: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FONDATION IMAGINE - INSTITUT DES MALADIES GÉNÉTIQUES, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), Universite De Paris
Application granted granted Critical
Publication of AU2018217404B2 publication Critical patent/AU2018217404B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AU2018217404A 2017-02-13 2018-02-12 Method for generating T cells progenitors Active AU2018217404B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305161 2017-02-13
EP17305161.6 2017-02-13
PCT/EP2018/053406 WO2018146297A1 (en) 2017-02-13 2018-02-12 Method for generating t cells progenitors

Publications (3)

Publication Number Publication Date
AU2018217404A1 AU2018217404A1 (en) 2019-09-05
AU2018217404A2 AU2018217404A2 (en) 2019-09-19
AU2018217404B2 true AU2018217404B2 (en) 2024-03-28

Family

ID=58185453

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018217404A Active AU2018217404B2 (en) 2017-02-13 2018-02-12 Method for generating T cells progenitors

Country Status (17)

Country Link
US (5) US20200046767A1 (enExample)
EP (2) EP3580330B1 (enExample)
JP (2) JP7164798B2 (enExample)
KR (1) KR102666158B1 (enExample)
CN (1) CN110506110B (enExample)
AU (1) AU2018217404B2 (enExample)
BR (1) BR112019016672A8 (enExample)
CA (1) CA3053294A1 (enExample)
DK (1) DK3580330T3 (enExample)
ES (1) ES2931530T3 (enExample)
HU (1) HUE060548T2 (enExample)
IL (1) IL268641B2 (enExample)
MA (1) MA47541A (enExample)
PL (1) PL3580330T3 (enExample)
PT (1) PT3580330T (enExample)
WO (1) WO2018146297A1 (enExample)
ZA (1) ZA201905470B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2931530T3 (es) * 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T
CA3077344A1 (en) * 2017-09-29 2019-04-04 Regents Of The University Of Minnesota Methods of making, expanding, and using a human progenitor t cell
EP3700334B1 (en) 2017-10-27 2026-04-08 Immunebridge Inc. Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
EP3847243A1 (en) * 2018-09-07 2021-07-14 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
WO2020223517A1 (en) * 2019-05-01 2020-11-05 Transfusion Health, Llc Methods of making oligopotent and unipotent precursors
CA3144640A1 (en) * 2019-06-24 2020-12-30 Children's Hospital Los Angeles Bcl11b overexpression to enhance human thymopoiesis and t cell function
EP4058562A4 (en) * 2019-11-14 2023-12-20 Zandstra, Peter William MEDIA FORMULATIONS AND PROCESSES FOR PRODUCING PROGENITOR T CELLS
WO2021200901A1 (ja) * 2020-03-31 2021-10-07 国立大学法人京都大学 Ｔ前駆細胞の製造方法
CN116615461A (zh) 2020-11-30 2023-08-18 醣基生医股份有限公司 用于富集细胞的抗体
CA3209946A1 (en) * 2021-03-05 2022-09-09 Matthew Angel Engineered immune cell therapies
EP4347793A1 (en) * 2021-05-25 2024-04-10 Universiteit Gent Generating t cell precursors via agonizing tumor necrosis factor receptor 2
US20260152721A1 (en) 2021-11-04 2026-06-04 Aphp (Assistance Publique - Hôpitaux De Paris) Method for generating nk cells
FR3130843A1 (fr) * 2021-12-21 2023-06-23 Universite Claude Bernard Lyon 1 Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt
KR20250150555A (ko) 2023-01-27 2025-10-20 노치 테라퓨틱스 (캐나다) 인크. 줄기세포/전구세포로부터 t 세포 계통 모집단을 생성하는 방법
KR20250152088A (ko) * 2023-02-22 2025-10-22 메이라지티엑스 셀 테라피스 흉선 재생 방법
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
WO2025219552A1 (en) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
CN121969764A (zh) * 2024-08-29 2026-05-01 京东方科技集团股份有限公司 引物设计、疾病分型诊断方法及装置、组合物、试剂盒及其用途
CN119709836B (zh) * 2024-12-21 2025-08-08 湖南农业大学 OsProT2基因在调控水稻镉含量、镉耐受性及产量中的应用和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016055396A1 (fr) * 2014-10-06 2016-04-14 Assistance Publique - Hopitaux De Paris Méthode de génération de progéniteurs de cellules t

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
WO1999028486A1 (en) 1997-12-04 1999-06-10 Duke University Methods of isolating and using cd7+cd34-lin-hematopoietic cells
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
CA2737193A1 (en) 2008-09-12 2010-03-18 Universidade Federal De Sao Paulo - Unifesp Ischemic tissue cell therapy
US8772028B2 (en) * 2008-11-07 2014-07-08 Sunnybrook Health Sciences Centre CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
US8871510B2 (en) 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
EP3590520B1 (en) 2010-04-09 2021-12-29 Fred Hutchinson Cancer Research Center Compositions for providing hematopoietic function without hla matching
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2013086436A1 (en) * 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US20150352180A1 (en) 2013-01-11 2015-12-10 The Trustee Of The University Of Pennsylvania Notch Ligand Bound Biocompatible Substrates And Their Use In Bone Formation
EP3027755B1 (en) * 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
JP6661544B2 (ja) * 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したｔ細胞の自動生成法
WO2016039933A1 (en) 2014-09-11 2016-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral vector for treating hemoglobin disorders
US11555207B2 (en) * 2015-06-17 2023-01-17 The Uab Research Foundation CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
US12076342B2 (en) 2016-04-08 2024-09-03 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
ES2931530T3 (es) * 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016055396A1 (fr) * 2014-10-06 2016-04-14 Assistance Publique - Hopitaux De Paris Méthode de génération de progéniteurs de cellules t

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OHISHI K et al., ‘The Notch ligand, Delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells’, Blood. (2001), vol. 98, no.5, pages 1402-1407. *
REIMANN C et al., ‘Human T-Lymphoid Progenitors Generated in a Feeder-Cell-Free Delta-Like-4 Culture System Promote T-Cell Reconstitution in NOD/SCID/[gamma]c-/- Mice’, STEM CELLS. (2012), vol. 30, no. 8, pages 1771-1780. *

Also Published As

Publication number Publication date
US20230293586A1 (en) 2023-09-21
US11638723B2 (en) 2023-05-02
PT3580330T (pt) 2022-12-06
AU2018217404A1 (en) 2019-09-05
BR112019016672A8 (pt) 2022-11-22
US11642376B2 (en) 2023-05-09
CA3053294A1 (en) 2018-08-16
US20210169935A1 (en) 2021-06-10
IL268641B1 (en) 2024-06-01
WO2018146297A1 (en) 2018-08-16
US20200390817A1 (en) 2020-12-17
JP7164798B2 (ja) 2022-11-02
RU2019125600A (ru) 2021-03-15
ES2931530T3 (es) 2022-12-30
JP2020513844A (ja) 2020-05-21
PL3580330T3 (pl) 2023-01-16
EP4067482A1 (en) 2022-10-05
AU2018217404A2 (en) 2019-09-19
US20210169934A1 (en) 2021-06-10
CN110506110A (zh) 2019-11-26
EP3580330B1 (en) 2022-08-31
RU2019125600A3 (enExample) 2021-11-03
ZA201905470B (en) 2024-12-18
US11426430B2 (en) 2022-08-30
HUE060548T2 (hu) 2023-03-28
IL268641B2 (en) 2024-10-01
EP3580330A1 (en) 2019-12-18
BR112019016672A2 (pt) 2020-04-14
MA47541A (fr) 2019-12-18
IL268641A (en) 2019-10-31
KR102666158B1 (ko) 2024-05-16
KR20190117550A (ko) 2019-10-16
CN110506110B (zh) 2024-09-06
DK3580330T3 (da) 2022-12-05
JP2022185024A (ja) 2022-12-13
US20200046767A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
US20230293586A1 (en) Method for generating t cells progenitors
JP7777884B2 (ja) ＣＤ８α＋β＋細胞傷害性Ｔ細胞の製造方法
JP5861191B2 (ja) ミエロイド系血液細胞の製造方法
US12071635B2 (en) Method for generating T-cell progenitors
JP7491532B2 (ja) ＨｖＧ疾患の処置における使用のためのＣＡＲ
KR100858857B1 (ko) 항원특이적 세포상해성 ｔ 세포 확대배양방법
AU2009311232B2 (en) Human progenitor T-cells
KR20170007449A (ko) 조혈 전구체 세포의 lilrb2 및 노치 매개 증식
TW202216174A (zh) 使ｎｋ細胞與抗體之結合穩定化之方法及其利用
HK40081656A (en) Method for generating t cells progenitors
RU2797260C2 (ru) Способ получения предшественников т-клеток
HK40017982A (en) Method for generating t cells progenitors
HK40017982B (en) Method for generating t cells progenitors
IL324860A (en) CarthyTreg cells, their compositions and uses in immunotherapy
HK40063050A (en) Car for use in the treatment of hvg disease

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 16 AUG 2019

PC1 Assignment before grant (sect. 113)

Owner name: UNIVERSITE DE PARIS

Free format text: FORMER APPLICANT(S): UNIVERSITE PARIS DESCARTES; FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Free format text: FORMER APPLICANT(S): UNIVERSITE PARIS DESCARTES; FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Owner name: FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES

Free format text: FORMER APPLICANT(S): UNIVERSITE PARIS DESCARTES; FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Free format text: FORMER APPLICANT(S): UNIVERSITE PARIS DESCARTES; FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

HB Alteration of name in register

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Free format text: FORMER NAME(S): UNIVERSITE DE PARIS; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Owner name: FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES

Free format text: FORMER NAME(S): UNIVERSITE DE PARIS; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Free format text: FORMER NAME(S): UNIVERSITE DE PARIS; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Owner name: UNIVERSITE PARIS CITE

Free format text: FORMER NAME(S): UNIVERSITE DE PARIS; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ANDRE, ISABELLE; CAVAZZANA, MARINA; MA, KUIYING; TCHEN, JOHN; SOHEILI, TAYEBEH-SHABI AND DEVI MOIRANGTHEM, RANJITA

FGA Letters patent sealed or granted (standard patent)